Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Status:
Active, not recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.

Phase 2

Fudan University